{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:30:35Z","timestamp":1770892235541,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ctrv.2021.102265","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:21:26Z","timestamp":1628144486000},"page":"102265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pleural mesothelioma (PM) \u2013 The status of systemic therapy"],"prefix":"10.1016","volume":"100","author":[{"given":"Wanyuan","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2021.102265_b0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/path.1700120212","article-title":"Malignant tumor arising from endothelium of peritoneum, and producing mucoid ascitic fluid","volume":"12","author":"Miller","year":"1908","journal-title":"J Pathol Bacteriol"},{"issue":"10272","key":"10.1016\/j.ctrv.2021.102265_b0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"10026","key":"10.1016\/j.ctrv.2021.102265_b0020","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2021.102265_b0025","unstructured":"WHO Classification of Tumours Editorial Board. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 5th ed. Lyon: IARC [in press]."},{"issue":"8","key":"10.1016\/j.ctrv.2021.102265_b0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9948","key":"10.1016\/j.ctrv.2021.102265_b0035","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0040","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is Radiotherapy Useful for treating pain in mesothelioma?: A phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102265_b0045","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.ejca.2011.05.012","article-title":"Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma","volume":"47","author":"Jenkins","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6601957","article-title":"A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma","volume":"91","author":"Bydder","year":"2004","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2007.05.022","article-title":"A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma","volume":"84","author":"O'Rourke","year":"2007","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102265_b0060","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102265_b0065","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial","volume":"37","author":"Bayman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102265_b0070","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","volume":"14","author":"Gomez","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102265_b0075","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0019-5278.146897","article-title":"Global mesothelioma epidemic: Trend and features","volume":"18","author":"Bianchi","year":"2014","journal-title":"Indian J Occup Environ Med"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102265_b0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0095","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","article-title":"Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based C. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdj073","article-title":"A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial","volume":"17","author":"O'Brien","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102265_b0110","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0169-5002(03)91714-4","article-title":"O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma","volume":"41","author":"Boyer","year":"2003","journal-title":"Lung Cancer"},{"issue":"28","key":"10.1016\/j.ctrv.2021.102265_b0115","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102265_b0125","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0130","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102265_b0140","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","article-title":"Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901","volume":"21","author":"Dudek","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102265_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102265_b0165","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.22366","article-title":"Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma","volume":"109","author":"Fennell","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102265_b0180","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102265_b0185","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/1759-7714.13490","article-title":"Amrubicin in previously treated patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Ikeda","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2021.102265_b0190","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res Notes"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e3181cae90e","article-title":"Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study","volume":"34","author":"Tourkantonis","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102265_b0200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102265_b0205","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2021.39.15_suppl.8507","article-title":"A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102265_b0210","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102265_b0215","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"OA 02.01 Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J Thoracic Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000029460","article-title":"Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma","volume":"67","author":"Konig","year":"2000","journal-title":"Respiration"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102265_b0225","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102265_b0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0235","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102265_b0240","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102265_b0245","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0250","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0255","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102265_b0260","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102265_b0265","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102265_b0270","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102265_b0275","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102265_b0280","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0285","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0295","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0300","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0305","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0310","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0315","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","volume":"75","author":"Kao","year":"2012","journal-title":"Lung Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2021.102265_b0320","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2021.102265_b0325","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102265_b0330","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ctrv.2021.102265_b0335","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102265_b0340","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102265_b0345","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"28","key":"10.1016\/j.ctrv.2021.102265_b0350","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0355","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102265_b0360","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2020.38.15_suppl.9004","article-title":"Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): results of Italian Rames Study","volume":"38","author":"Pagano","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102265_b0365","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102265_b0370","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102265_b0380","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102265_b0385","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102265_b0390","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102265_b0395","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10_suppl","key":"10.1016\/j.ctrv.2021.102265_b0400","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"Phase II Trial of Pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): Final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thoracic Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102265_b0405","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2021.102265_b0410","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0415","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ctrv.2021.102265_b0420","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jtho.2021.01.323","article-title":"PS01.11 Nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM Phase 3 trial","volume":"16","author":"Fennell","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0430","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0435","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102265_b0440","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102265_b0445","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102265_b0450","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102265_b0455","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102265_b0465","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102265_b0470","doi-asserted-by":"crossref","first-page":"9058","DOI":"10.1200\/JCO.2020.38.15_suppl.9058","article-title":"Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma","volume":"38","author":"Zauderer","year":"2020","journal-title":"J Clin Oncol"},{"issue":"237","key":"10.1016\/j.ctrv.2021.102265_b0475","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts for FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102265_b0480","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized","volume":"37","author":"Fennell","year":"2019","journal-title":"Phase II Study J Clin Oncol"},{"issue":"49","key":"10.1016\/j.ctrv.2021.102265_b0485","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2021.102265_b0490","doi-asserted-by":"crossref","first-page":"8558","DOI":"10.1200\/JCO.2021.39.15_suppl.8558","article-title":"A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102265_b0495","article-title":"Integrated genomics identify novel immunotherapy targets for malignant mesothelioma","author":"Nastase","year":"2020","journal-title":"MedRxiv"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102265_b0500","doi-asserted-by":"crossref","first-page":"e1457","DOI":"10.1634\/theoncologist.2020-0610","article-title":"A phase II trial of alisertib (MLN8237) in salvage malignant mesothelioma","volume":"25","author":"Gay","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0505","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod Pathol"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102265_b0510","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.ctrv.2021.102265_b0515","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2021.102265_b0520","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102265_b0525","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102265_b0530","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102265_b0535","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102265_b0540","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102265_b0545","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102265_b0550","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.4049\/jimmunol.1102209","article-title":"Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients","volume":"187","author":"Alfaro","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102265_b0555","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl Lung Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:25:28Z","timestamp":1759656328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221001134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":111,"alternative-id":["S0305737221001134"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102265","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleural mesothelioma (PM) \u2013 The status of systemic therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102265"}}